|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-7-30
|
|
pubmed:abstractText |
Individuals expressing the polymorphic CYP3A5 enzyme might show a more than average efficiency in the metabolism of lovastatin, simvastatin and atorvastatin. We studied whether the expression of CYP3A5 is associated with an impaired lipid-lowering response to statins in 69 Caucasian patients. Lovastatin, simvastatin and atorvastatin were significantly less effective in CYP3A5 expressors than in non-expressors. The mean serum total cholesterol concentration at 1 year was 23% higher (P = 0.0014) and the mean serum low-density lipoprotein cholesterol concentration was 24% higher (P = 0.036) in subjects possessing the CYP3A5*1 allele (CYP3A5 expressors, n = 7) than in subjects homozygous for the CYP3A5*3 allele (non-expressors, n = 39). The mean percentage reduction in serum total cholesterol from baseline was significantly smaller in CYP3A5 expressors than in non-expressors (17% versus 31%, P = 0.026). No association between hypolipidemic efficacy and CYP3A5 polymorphism was observed among 23 subjects taking statins that are not dependent on CYP3A5 (fluvastatin, pravastatin). These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin,
http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0960-314X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
523-5
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15284534-Aged,
pubmed-meshheading:15284534-Anticholesteremic Agents,
pubmed-meshheading:15284534-Cholesterol,
pubmed-meshheading:15284534-Cholesterol, LDL,
pubmed-meshheading:15284534-Cytochrome P-450 CYP3A,
pubmed-meshheading:15284534-Cytochrome P-450 Enzyme System,
pubmed-meshheading:15284534-Female,
pubmed-meshheading:15284534-Genotype,
pubmed-meshheading:15284534-Heptanoic Acids,
pubmed-meshheading:15284534-Homozygote,
pubmed-meshheading:15284534-Humans,
pubmed-meshheading:15284534-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:15284534-Lovastatin,
pubmed-meshheading:15284534-Male,
pubmed-meshheading:15284534-Polymorphism, Genetic,
pubmed-meshheading:15284534-Pyrroles,
pubmed-meshheading:15284534-Simvastatin
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
|
|
pubmed:affiliation |
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
